Hillhouse-Backed Biotech Firm I-Mab Eyes $100M In US IPO

I-Mab Biopharma, a Chinese-clinical stage biopharmaceutical company, has filed for an up to US$100 million IPO of American Depository Shares (ADS) on the Nasdaq on Tuesday. Founded in 2016, I-Mab offers best-in-class and first-in-class biologics to treat cancer and autoimmune disorders. The company’s predecessor is Third Venture Biopharma (Nanjing) Co., Ltd. which was launched in […]

Hillhouse-Backed Biotech Firm I-Mab Eyes $100M In US IPO comes originally from China Money Network. All Rights Reserved.

Read the original article: China Money Network